Cogent Biosciences' CGT1145 shows best-in-class potential; IND in 2026
Cogent Biosciences announced positive preclinical data for CGT1145, its novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association Congress. The data highlights CGT1145's potential best-in-class properties, including over 100x selectivity compared to JAK2 WT and JAK1/3 isoforms, high oral bioavailability, and low clearance. The company remains on track to submit an Investigational New Drug (IND) application for CGT1145 in 2026, aiming to address myeloproliferative neoplasms with improved hematologic tolerability.
Key Highlights
- Preclinical data for CGT1145 presented at 2026 EHA Congress.
- CGT1145 shows >100x selectivity over JAK2 WT and JAK1/3 isoforms.
- CGT1145 exhibits high oral bioavailability and low clearance.
- Investigational New Drug (IND) application for CGT1145 on track for 2026.
- JAK2 V617F mutation affects ~95% of polycythemia vera patients.
- JAK2 V617F mutation affects ~50% of primary myelofibrosis patients.
Price Impact
More from COGT
Cogent Biosciences' bezuclastinib shows 65% ORR in AdvSM; NDA in June 2026
Cogent Biosciences bezuclastinib combo shows 16.5-mo PFS in GIST; FDA Priority Review
Cogent Biosciences' bezuclastinib NDA for GIST accepted with Priority Review